Tumor Antigen Targeted Monoclonal Antibodies |
Cetuximab (Bristol-Myers Squibb, Eli Lilly) |
EGFR antagonist |
IgG1 |
III/IV (FDA-approved HNSCC, NSCLC, colon cancer) |
Phase III/IV |
Panitumumab (Amgen) |
EGFR antagonist |
IgG2 |
III/IV (FDA-approved colon cancer) |
Phase II/III |
Onartuzumab (Genentech) |
cMet antagonist (single-arm Fab) |
IgG1 |
II/III |
--- |
Pertuzumab (Genentech) |
HER2 antagonist |
IgG1 |
III |
--- |
AV-203 (Aveo) |
HER3 antagonist |
IgG1 |
I |
Phase I (monotherapy; cetuximab combination) |
MM-121 (Merck) |
HER3 antagonist |
IgG2 |
I/II |
--- |
RO5479599 (Roche) |
HER3 antagonist |
Glyco-engineered |
I/II |
--- |
Cixutumumab (Eli Lilly) |
IGFR antagonist |
IgG1 |
II |
Phase 0-II (neoadjuvant monotherapy; cetuximab combination) |
Cytokine Targeted Monoclonal Antibodies |
Bevacizumab (Genentech) |
VEGF neutralizer |
IgG1 |
III/IV (FDA approved in NSCLC, colon) |
Phase III (platinum chemotherapy +/−) |
Ficlatuzumab (Aveo) |
HGF neutralizer |
IgG1 |
I/II |
Phase I (cetuximab combination; cisplatin-radiation combination) |
AMG 102 (Amgen) |
HGF neutralizer |
IgG2 |
I/II |
--- |
Fresolimumab (Genzyme) |
TGF-β neutralizer |
IgG4 |
|
--- |
Siltuximab (Janssen Biotech) |
IL-6 neutralizer |
IgG1 |
I/II |
--- |
TNF Receptor Targeted Monoclonal Antibodies |
CP-870,893 (Pfizer) |
CD40 agonist |
IgG2 |
I |
--- |
OX40 mAb (AgonOx, Providence Health) |
OX40 agonist |
IgG2 |
I |
--- |
Urelumab (Bristol-Myers Squibb) |
CD137 agonist |
IgG4 |
I |
--- |
PF-05082566 (Pfizer) |
CD137 agonist |
IgG2 |
I |
--- |
Immune Checkpoint Targeted Monoclonal Antibodies |
Ipilimumab (Bristol-Myers Squibb) |
CTLA4 |
IgG1 |
III/IV (FDA approved in melanoma |
Phase I (cetuximab-radiation combination) |
Tremelimumab (Pfizer) |
CTLA4 |
IgG2 |
III |
--- |
Nivolumab (Bristol-Myers Squibb) |
PD-1 |
IgG4 |
I/II/III |
--- |
Lambrolizumab (Merck) |
PD-1 |
IgG4 |
I/II |
--- |
BMS-936559 (Bristol-Myers Squibb) |
PD-L1 |
IgG4 |
I |
--- |